Minerva Neurosciences | NERV - Cash And Equivalent


Minerva Neurosciences reported $82.3M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Adma Biologics USD 87.63M 26.24M Dec/2025
ALKERMES USD 388.57M 227.88M Dec/2025
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
AstraZeneca USD 8.14B 1.08B Sep/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 240.63M 27.39M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025